<DOC>
	<DOCNO>NCT01537198</DOCNO>
	<brief_summary>Approximately 600 pediatric patient prescribe palivizumab ( Synagis ) prophylaxis usual practice accord approved Korean product label register observational study . Baseline data obtain enrollment include demographic , gestational age , birth weight underlying disease complication especially regard respiratory disease cardiovascular disease . At routine visit Synagis administration , occur accord usual medical practice , information Synagis prophylaxis , concomitant medication , adverse event collect 30 day last administration Synagis .</brief_summary>
	<brief_title>Surveillance Synagis Korean Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Pediatric patient high risk RSV disease , need prevention serious low respiratory tract disease cause RSV , meet follow criterion : Preterm newborn infant infant bear 35 week gestation less , less 6 month age onset RSV season ( RSV season define Oct. 1 follow Mar . 31 ) . Newborn infant , infant , child 2 year age require treatment bronchopulmonary dysplasia ( BPD ) within last 6 month precede RSV season ( RSV season define Oct. 1 follow Mar . 31 ) . Newborn infant , infant , child 2 year age hemodynamically significant congenital heart disease ( CHD ) . Obtained authorization form use personal and/or health data legal representative prior entry study . Contraindications accord approve label .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Postmarketing Drug Surveillance</keyword>
</DOC>